John Sullivan, MD
Ophthalmology · Jacksonville, FLNPI 1619977345
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $10,231 of the $12,503 with a category attached, or 81.8%. US Retina LLC accounts for 81.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $5,040 and has fallen 88.3% since, to $588 in 2025.
Across 93 payments — averaging $134.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$10K
- Genentech USA, Inc.$728
- Regeneron Healthcare Solutions, Inc.$420
- AbbVie$396
- Alimera Sciences, Inc.$134
- Astellas Pharma US Inc$108
- plus $486 from 14 others
What the payments were for
- Food & beverage$2,27218%
- Ownership interest$10,23182%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $10,231 |
| Genentech USA, Inc. | 20 | $728 |
| Regeneron Healthcare Solutions, Inc. | 18 | $420 |
| AbbVie(2 entities) | 19 | $396 |
| Alimera Sciences, Inc. | 7 | $134 |
| Astellas Pharma US Inc | 2 | $108 |
| Stryker | 1 | $106 |
| Halozyme Inc | 4 | $72 |
| Aerie Pharmaceuticals, Inc. | 3 | $43 |
| Apellis Pharmaceuticals, Inc. | 2 | $41 |
| Johnson & Johnson Vision Care, Inc. | 1 | $40 |
| UCB, Inc. | 1 | $27 |
| Eyepoint US, Inc. | 2 | $25 |
| Eyevance Pharmaceuticals LLC | 1 | $24 |
| Bristol Myers Squibb | 1 | $20 |
| Novartis | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Pfizer | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$349
- NA$213
- COLORADO$106
- VSP SYSTEM, VSP CRANIAL$106
How this compares
$12,503 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 87 | $172,050 |
| Prednisolone Acetate | 575 | $23,870 |
| Latanoprost | 1,531 | $15,134 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,024 | $14,031 |
| LumiganBimatoprost | 34 | $8,926 |
| Bromfenac Sodium | 77 | $8,115 |
| RhopressaNetarsudil Mesylate | 22 | $7,633 |
| Alphagan PBrimonidine Tartrate | 14 | $6,040 |
| RocklatanNetarsudil Mesylat/Latanoprost | 18 | $5,903 |
| Brimonidine Tartrate | 555 | $5,649 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 43 | $5,604 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 507 | $5,304 |
| Dorzolamide Hcl | 301 | $5,089 |
| Brinzolamide | 34 | $4,482 |
| Acetazolamide | 90 | $4,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $420 | $172,05087 claims |
| AbbVieLumigan, Alphagan P, Combigan | $396 | $19,22367 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $43 | $13,53640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Jacksonville
- Syril DorairajJacksonville$432K
- Frank BowdenJacksonville$169K
- David KostickJacksonville$108K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.